Far from the Eyes, Close to the Heart: Dysbiosis of Gut Microbiota and Cardiovascular Consequences

Current Cardiology Reports

Volumn 16, Issue 11, 2014, Pages 1-7

  Serino, Matteo ^a,b   Blasco Baque, Vincent ^a,b,c   Nicolas, Simon ^a,b   Burcelin, Remy ^a,b  

^a INSERM   (France)

^b Université de Toulouse   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Cardiovascular diseases; Gut microbiota; High fat diet; Inflammation; Metagenomics; Protein rich diet

Indexed keywords

AZITHROMYCIN; PLACEBO; VANCOMYCIN; PROBIOTIC AGENT;

AGGREGATIBACTER ACTINOMYCETEMCOMITANS; ANTIBIOTIC THERAPY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; CARDIOVASCULAR DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DYSBIOSIS; ESCHERICHIA COLI; FUSOBACTERIUM NUCLEATUM; HEART INFARCTION; HUMAN; INTESTINE FLORA; LACTOBACILLUS RHAMNOSUS; METABOLIC DISORDER; METHANOGEN; METHANOMASSILIICOCCUS LUMINYENSIS; MOUTH FLORA; NONHUMAN; PERIODONTAL DISEASE; PORPHYROMONAS GINGIVALIS; PREVOTELLA INTERMEDIA; PSEUDOMONAS; REVIEW; ANIMAL; COMPLICATION; DISEASE MODEL; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TRACT; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; MICROBIOLOGY; MICROFLORA; MOUSE; PERIODONTITIS; RAT;

ANIMALS; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; DYSBIOSIS; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL TRACT; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MICE; MICROBIOTA; PERIODONTITIS; PROBIOTICS; RATS;

EID: 84910619978     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-014-0540-1     Document Type: Review

References (61)

1. Bjorksten B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol. 2001;108(4):516–20.
2. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65. doi:10.1038/nature08821. This was the first study to list the human gut microbiota gene repertoire.
3. Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, et al. Dietary intervention impact on gut microbial gene richness. Nature. 2013;500(7464):585–8. doi:10.1038/nature12480. This study demonstrates that diet regimens also impact on gut microbiota gene function, other than gut microbiota taxonomy.
4. Burcelin R, Serino M, Chabo C, Blasco-Baque V, Amar J. Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. Acta Diabetol. 2011;48(4):257–73. doi:10.1007/s00592-011-0333-6.
5. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104(3):979–84.
6. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–31.
7. Reinhardt C, Bergentall M, Greiner TU, Schaffner F, Ostergren-Lunden G, Petersen LC, et al. Tissue factor and PAR1 promote microbiota-induced intestinal vascular remodelling. Nature. 2012;483(7391):627–31. doi:10.1038/nature10893.
8. Shanahan F. The host-microbe interface within the gut. Best Pract Res Clin Gastroenterol. 2002;16(6):915–31.
9. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013;500(7461):232–6. doi:10.1038/nature12331.
10. Chung H, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB, et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell. 2012;149(7):1578–93. doi:10.1016/j.cell.2012.04.037.
11. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–72.
12. Serino M, Luche E, Gres S, Baylac A, Berge M, Cenac C, et al. Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. Gut. 2012;61(4):543–53. doi:10.1136/gutjnl-2011-301012. This study demonstrates that gut microbiota identifies different metabolic profiles and that the same metabolic profile can also be characterized by a different gut microbiota.
13. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470–81.
14. Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. Faseb J. 2008;22(7):2416–26.
15. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793–801.
16. Serino M, Chabo C, Burcelin R. Intestinal MicrobiOMICS to define health and disease in human and mice. Curr Pharm Biotechnol. 2012;13(5):746–58.
17. Tomasello G, Bellavia M, Palumbo VD, Gioviale MC, Damiani P, Lo Monte AI. From gut microflora imbalance to mycobacteria infection: is there a relationship with chronic intestinal inflammatory diseases? Ann Ital Chir. 2011;82(5):361–8.
18. Serban DE. Gastrointestinal cancers: influence of gut microbiota, probiotics and prebiotics. Cancer Lett. 2014;345(2):258–70. doi:10.1016/j.canlet.2013.08.013.
19. Haahtela T, Holgate S, Pawankar R, Akdis CA, Benjaponpitak S, Caraballo L, et al. The biodiversity hypothesis and allergic disease: world allergy organization position statement. World Allergy Organ J. 2013;6(1):3. doi:10.1186/1939-4551-6-3.
20. Serino M, Luche E, Chabo C, Amar J, Burcelin R. Intestinal microflora and metabolic diseases. Diabetes Metab. 2009
21. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022–3.
22. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102(31):11070–5.
23. Wu X, Ma C, Han L, Nawaz M, Gao F, Zhang X, et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol. 2010;61(1):69–78. doi:10.1007/s00284-010-9582-9.
24. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119(10):812–9. doi:10.1016/j.amjmed.2006.02.031.
25. In: Fuster V, Kelly BB, editors. Promoting cardiovascular health in the developing world: a critical challenge to achieve global health. The National Academies Collection: Reports funded by National Institutes of Health. Washington (DC)2010.
26. Ovbiagele B, Goldstein LB, Higashida RT, Howard VJ, Johnston SC, Khavjou OA, et al. Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association. Stroke; J cereb circ. 2013;44(8):2361–75. doi:10.1161/STR.0b013e31829734f2.
27. Dumas ME, Kinross J, Nicholson JK. Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease. Gastroenterology. 2014;146(1):46–62. doi:10.1053/j.gastro.2013.11.001.
28. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–85. doi:10.1038/nm.3145. This study provides the mechanism through which gut microbiota promotes atherosclerosis.
29. Wright SD, Burton C, Hernandez M, Hassing H, Montenegro J, Mundt S, et al. Infectious agents are not necessary for murine atherogenesis. J Exp Med. 2000;191(8):1437–42.
30. Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA. 2005;293(21):2641–7. doi:10.1001/jama.293.21.2641.
31. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352(16):1637–45. doi:10.1056/NEJMoa043526.
32. Lam V, Su J, Koprowski S, Hsu A, Tweddell JS, Rafiee P, et al. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J. 2012;26(4):1727–35. doi:10.1096/fj.11-197921.
33. Nguyen TD, Kang JH, Lee MS. Characterization of Lactobacillus plantarum PH04, a potential probiotic bacterium with cholesterol-lowering effects. Int J Food Microbiol. 2007;113(3):358–61. doi:10.1016/j.ijfoodmicro.2006.08.015.
34. Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology. 2011;140(3):976–86. doi:10.1053/j.gastro.2010.11.049.
35. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575–84. doi:10.1056/NEJMoa1109400.
36. Goldsmith JR, Sartor RB. The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. J Gastroenterol. 2014;49(5):785–98. doi:10.1007/s00535-014-0953-z.
37. Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A. 2006;103(33):12511–6. doi:10.1073/pnas.0601056103.
38. Lee YK, Mazmanian SK. Has the microbiota played a critical role in the evolution of the adaptive immune system? Science. 2010;330(6012):1768–73. doi:10.1126/science.1195568.
39. Koren O, Spor A, Felin J, Fak F, Stombaugh J, Tremaroli V, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4592–8. doi:10.1073/pnas.1011383107.
40. Amar J, Serino M, Lange C, Chabo C, Iacovoni J, Mondot S, et al. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia. 2011;54(12):3055–61. doi:10.1007/s00125-011-2329-8. This study provides the first evidence for the existence of a blood microbiota.
41. Karlsson FH, Fak F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012;3:1245. doi:10.1038/ncomms2266.
42. Roberfroid M. Prebiotics: the concept revisited. J Nutr. 2007;137(3 Suppl 2):830S–7S.
43. Roberfroid MB. Inulin-type fructans: functional food ingredients. J Nutr. 2007;137(11 Suppl):2493S–502S.
44. Wang J, Tang H, Zhang C, Zhao Y, Derrien M, Rocher E, et al. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J. 2014. doi:10.1038/ismej.2014.99.
45. Gan XT, Ettinger G, Huang CX, Burton JP, Haist JV, Rajapurohitam V, et al. Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circ Heart Fail. 2014;7(3):491–9. doi:10.1161/CIRCHEARTFAILURE.113.000978.
46. Brugere JF, Borrel G, Gaci N, Tottey W, O’Toole PW, Malpuech-Brugere C. Archaebiotics: proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular disease. Gut Microbes. 2014;5(1):5–10. doi:10.4161/gmic.26749.
47. Wang Z, Tang WH, Buffa JA, Fu X, Britt EB, Koeth RA, et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J. 2014;35(14):904–10. doi:10.1093/eurheartj/ehu002.
48. Underwood MA, Arriola J, Gerber CW, Kaveti A, Kalanetra KM, Kananurak A, et al. Bifidobacterium longum subsp. infantis in experimental necrotizing enterocolitis: alterations in inflammation, innate immune response, and the microbiota. Pediatr Res. 2014. doi:10.1038/pr.2014.102.
49. Ellis CL, Bokulich NA, Kalanetra KM, Mirmiran M, Elumalai J, Haapanen L, et al. Probiotic administration in congenital heart disease: a pilot study. J Perinatol: Off J Calif Perinat Assoc. 2013;33(9):691–7. doi:10.1038/jp.2013.41.
50. Albandar JM, Rams TE. Global epidemiology of periodontal diseases: an overview. Periodontol. 2002;29:7–10.
51. Lakhssassi N, Elhajoui N, Lodter JP, Pineill JL, Sixou M. Antimicrobial susceptibility variation of 50 anaerobic periopathogens in aggressive periodontitis: an interindividual variability study. Oral Microbiol Immunol. 2005;20(4):244–52. doi:10.1111/j.1399-302X.2005.00225.x.
52. Mattila KJ, Pussinen PJ, Paju S. Dental infections and cardiovascular diseases: a review. J Periodontol. 2005;76(11 Suppl):2085–8.
53. Blasco-Baque V, Kemoun P, Loubieres P, Roumieux M, Heymes C, Serino M, et al. [Impact of periodontal disease on arterial pressure in diabetic mice.]. Ann Cardiol Angeiol (Paris). 2012. doi:10.1016/j.ancard.2012.04.012.
54. Blasco-Baque V, Serino M, Vergnes JN, Riant E, Loubieres P, Arnal JF, et al. High-Fat diet induces periodontitis in mice through lipopolysaccharides (LPS) receptor signaling: protective action of estrogens. PLoS One. 2012;7(11):e48220. doi:10.1371/journal.pone.0048220.
55. Bullon P, Cordero MD, Quiles JL, Morillo JM, del Carmen Ramirez-Tortosa M, Battino M. Mitochondrial dysfunction promoted by Porphyromonas gingivalis lipopolysaccharide as a possible link between cardiovascular disease and periodontitis. Free Radic Biol Med. 2011;50(10):1336–43. doi:10.1016/j.freeradbiomed.2011.02.018.
56. Debelian GJ, Olsen I, Tronstad L. Systemic diseases caused by oral microorganisms. Endod Dent Traumatol. 1994;10(2):57–65.
57. Que YA, Moreillon P. Infective endocarditis. Nat Rev Cardiol. 2011;8(6):322–36. doi:10.1038/nrcardio.2011.43.
58. Calandrini CA, Ribeiro AC, Gonnelli AC, Ota-Tsuzuki C, Rangel LP, Saba-Chujfi E, et al. Microbial composition of atherosclerotic plaques. Oral Dis. 2014;20(3):e128–34. doi:10.1111/odi.12205.
59. Burcelin R, Luche E, Serino M, Amar J. The gut microbiota ecology: a new opportunity for the treatment of metabolic diseases? Front Biosci. 2009;14:5107–17.
60. Serino M, Blasco-Baque V, Burcelin R. Microbes on-air: gut and tissue microbiota as targets in type 2 diabetes. J Clin Gastroenterol. 2012;46:S27–8. doi:10.1097/MCG.0b013e318264e844.
61. Ussher JR, Lopaschuk GD, Arduini A. Gut microbiota metabolism of L-carnitine and cardiovascular risk. Atherosclerosis. 2013;231(2):456–61. doi:10.1016/j.atherosclerosis.2013.10.013.